Physician profile
Sarah E Breon
NPI 1538315395
$8,536.44
in general payments reported to CMS, 2019-2025
38 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $389 · 2021: $767 · 2022: $1,534 · 2023: $1,384 · 2024: $1,527 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,156.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,169.11 | 2019-2025 | |
| Novo Nordisk INC | $1,032.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $870.30 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $703.30 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $629.70 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $561.40 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $424.45 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $367.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.35 | 2020-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $317.93 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $305.31 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.92 | 2025 | Caplyta |
| Madrigal Pharmaceuticals | $221.56 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $166.74 | 2019-2025 | |
| Astellas Pharma US INC | $160.79 | 2019-2025 | Veozah |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $144.91 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.32 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $127.63 | 2019-2023 | Steglatro, Belsomra |
| Sanofi-Aventis U.S. LLC | $113.43 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $91.61 | 2021 | |
| Allergan, INC. | $58.96 | 2019-2020 | |
| Bioventus LLC | $52.39 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Paratek Pharmaceuticals, INC. | $37.95 | 2023 | Nuzyra |
| Philips North America LLC | $36.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2019 | |
| Alkermes, INC. | $26.61 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $26.09 | 2019-2020 | |
| Axsome Therapeutics, INC. | $21.84 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $18.75 | 2024 | Gvoke Hypopen |
| Verona Pharma, INC. | $17.80 | 2025 | Ohtuvayre |
| Amneal Pharmaceuticals LLC | $16.01 | 2019 | |
| Dexcom, INC. | $15.42 | 2025 | Dexcom G6 Transmitter |
| Ebi, LLC | $14.56 | 2025 | Biomet Ebi Bone Healing System |
| Abbott Laboratories | $14.51 | 2021 | |
| Heraeus Medical, LLC. | $14.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.93 | 2021 | |
| Apria Healthcare LLC | $11.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.22 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Breon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.